Head-To-Head Analysis: Shattuck Labs (STTK) & Its Peers

Shattuck Labs (NASDAQ:STTK) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Shattuck Labs to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Shattuck Labs and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Shattuck Labs Competitors	-9,051.23%	-201.20%	-30.64%

Valuation and Earnings

This table compares Shattuck Labs and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Shattuck Labs	$1.00 million	-$48.81 million	-9.41
Shattuck Labs Competitors	$727.61 million	$12.25 million	-10.28

Shattuck Labs’ peers have higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Shattuck Labs has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Shattuck Labs’ peers have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Shattuck Labs and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	9	3	3.08
Shattuck Labs Competitors	9792	15073	45355	1574	2.54

Shattuck Labs currently has a consensus target price of $13.70, indicating a potential upside of 185.36%. As a group, “Biotechnology” companies have a potential upside of 96.39%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, research analysts clearly believe Shattuck Labs is more favorable than its peers.

Institutional and Insider Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Shattuck Labs beats its peers on 9 of the 13 factors compared.

Shattuck Labs Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.